Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Effects of Talampanel on Patients With Advanced Parkinson`s Disease

Study:

Effects of Talampanel on Patients With Advanced Parkinson`s Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)

Rationale:

n/a

Purpose:

The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson`s disease. It is not clear why people with Parkinson`s disease develop involuntary movements (dyskinesias) but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements. Talampanel is a drug which blocks these receptors.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Dyskinesias
Parkinson Disease
Movement Disorders		 Drug: talampanel Phase 1/Phase 2

Verified by IVAX Research LLC March, 2008

Sponsored by: IVAX Research LLC
Information provided by: IVAX Research LLC
ClinicalTrials.gov identifier: NCT00036296

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Florida
Weston, Florida 33331
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.